22.418 articles found

Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.

Hudry J, Rinne JO, Keränen T, Eckert L, Cochran JM.

Ann Pharmacother · 2006-03-28

DOI: 10.1345/aph.1g454PMID: 16569799

Derivation of embryonic stem cells for cellular therapy: challenges and new strategies.

Taupin P.

Med Sci Monit · 2006-03-28

PMID: 16572064

A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.

Benbir G, Ozekmekçi S, Apaydin H, Delil S, Erginöz E.

Clin Neurol Neurosurg · 2006-03-27

DOI: 10.1016/j.clineuro.2006.02.002PMID: 16564615

Mutant lysosomal type 5 P-type ATPase ATP13A2 and its use for diagnosis and therapy of neurodegenerative disorders

KUBISCH CHRISTIAN PROF. DR, RAMIREZ ALFREDO.

· 2006-03-24

Oxidative stress in peripheral blood mononuclear cells from patients with Parkinson's disease: negative correlation with levodopa dosage.

Prigione A, Begni B, Galbussera A, Beretta S, Brighina L, Garofalo R, Andreoni S, Piolti R, Ferrarese C.

Neurobiol Dis · 2006-03-24

DOI: 10.1016/j.nbd.2006.01.013PMID: 16563783

Sudden onset of sleep and dopaminergic therapy in patients with restless legs syndrome.

Möller JC, Körner Y, Cassel W, Meindorfner C, Krüger HP, Oertel WH, Stiasny-Kolster K.

Sleep Med · 2006-03-22

DOI: 10.1016/j.sleep.2005.08.009PMID: 16554184

Therapeutic application of transcranial magnetic stimulation in Parkinson's disease: the contribution of expectation.

Strafella AP, Ko JH, Monchi O.

Neuroimage · 2006-03-20

DOI: 10.1016/j.neuroimage.2006.02.005PMID: 16545582

In vivo complementation of complex I by the yeast Ndi1 enzyme. Possible application for treatment of Parkinson disease.

Seo BB, Nakamaru-Ogiso E, Flotte TR, Matsuno-Yagi A, Yagi T.

J Biol Chem · 2006-03-16

DOI: 10.1074/jbc.m600922200PMID: 16543240

Bradykinesia in patients with Parkinson's disease having levodopa-induced dyskinesias.

Ghassemi M, Lemieux S, Jog M, Edwards R, Duval C.

Brain Res Bull · 2006-03-15

DOI: 10.1016/j.brainresbull.2006.02.015PMID: 16647580

Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases.

Popovic N, Brundin P.

Int J Pharm · 2006-03-10

DOI: 10.1016/j.ijpharm.2005.09.040PMID: 16529886

L-DOPA treatment of parkinsonian rats changes the expression of Src, Lyn and PKC kinases.

Napolitano M, Picconi B, Centonze D, Bernardi G, Calabresi P, Gulino A.

Neurosci Lett · 2006-03-09

DOI: 10.1016/j.neulet.2005.12.077PMID: 16529858

Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases.

Bodner RA, Outeiro TF, Altmann S, Maxwell MM, Cho SH, Hyman BT, McLean PJ, Young AB, Housman DE, Kazantsev AG.

Proc Natl Acad Sci U S A · 2006-03-06

DOI: 10.1073/pnas.0511256103PMID: 16537516